Clinical activity of abiraterone plus prednisone in docetaxel-naοve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer / 亚洲男科学杂志(英文版)
Asian Journal of Andrology
; (6): 131-136, 2019.
Article
Dans En
| WPRIM
| ID: wpr-1009681
Responsable en Bibliothèque :
WPRO
ABSTRACT
This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 146 patients with docetaxel-naïve group (103 cases) and docetaxel-resistant group (43 cases) were enrolled from the Shanghai Cancer Center (Shanghai, China) in this retrospective cohort study. The efficacy endpoints were prostate-specific antigen response rate, prostate-specific antigen progression-free survival, clinical/radiographic progression-free survival, and overall survival in response to abiraterone plus prednisone. Significantly higher prostate-specific antigen response rate was found in docetaxel-naïve group (54.4%, 56/103) compared to docetaxel-resistant group (34.9%, 15/43) (P = 0.047). In addition, significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months, P = 0.005), clinical or radiographic progression-free survival (17.0 vs 12.5 months, P = 0.003), and overall survival (27.0 vs 18.0 months, P = 0.016) were found in docetaxel-naïve group compared to docetaxel-resistant group, respectively. The univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall survival. To sum up, our data suggested that abiraterone plus prednisone was efficient in both docetaxel-naïve and docetaxel-resistant Chinese patients. Moreover, higher PSA response rate and longer overall survival were observed in the docetaxel-naïve group, which suggested that abiraterone was more effective for docetaxel- naïve patients than for docetaxel failures.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Prednisone
/
Chine
/
Taux de survie
/
Études rétrospectives
/
Résultat thérapeutique
/
Survie sans rechute
/
Évolution de la maladie
/
Antinéoplasiques hormonaux
/
Association de médicaments
/
Tumeurs prostatiques résistantes à la castration
Limites du sujet:
Aged
/
Aged80
/
Humans
/
Male
Pays comme sujet:
Asia
langue:
En
Texte intégral:
Asian Journal of Andrology
Année:
2019
Type:
Article